Has Yousuf Gandapur, MD received payments from drug or device companies?

Yes. Drug and device makers reported $9,568 in general payments to Yousuf Gandapur, MD across 161 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Yousuf Gandapur, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Yousuf Gandapur, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Yousuf Gandapur, MD

Interventional Cardiology · Wellington, FLNPI 1790126753

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,240 of the $9,568 with a category attached, or 65.2%. 21 manufacturers reported payments, led by Abbott at 27.5% of the total. Reporting peaked in 2024 at $4,152 and has fallen 89.1% since, to $454 in 2025.

$9,568in general payments, 2019–2025

Across 161 payments — averaging $59.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$3K
Boston Scientific$1K
Inari Medical, Inc.$1K
Edwards Lifesciences$1K
AstraZeneca$563
Boehringer Ingelheim$433
plus $2K from 15 others

What the payments were for

Travel & lodging$3,11133%
Food & beverage$6,24065%
Education$2182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	37	$2,635
Boston Scientific	12	$1,312
Inari Medical, Inc.	7	$1,294
Edwards Lifesciences	17	$1,225
AstraZeneca	18	$563
Boehringer Ingelheim	22	$433
Pfizer	13	$254
Abiomed	4	$242
Cvrx, Inc.	2	$231
Shockwave Medical, Inc	2	$199
Terumo Medical Corporation	2	$156
E.r. Squibb & Sons, L.L.C.	7	$154
Acist Medical Systems, Inc.	1	$150
Penumbra, Inc.	3	$130
Asahi Intecc USA, Inc.	2	$129
Cordis US CORP.	1	$102
Chiesi USA, Inc.	2	$94
Amgen	4	$90
Astellas Pharma US Inc	1	$88
Johnson & Johnson	2	$56
Biotronik Inc.	2	$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OPTIS$1,464
CT THROMBECTOMY SYSTEM KIT$1,187
FLOWTRIEVER CATHETER, S$1,187
Watchman$433
Edwards SAPIEN 3 Transcatheter Heart Valve$327
Barostim Neo System$211
WATCHMAN Access System$168
CVI SYSTEMS$150
Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$144
COROFLOW$138
BRILINTA$125
Impella$125
ANGIO-SEAL$123
SAPIEN 3 Ultra RESILIA$120
JOT DX$114
PERIPHERAL VASCULAR$112
MYNX CONTROL$102

How this compares

$9,568 in reported general payments places this provider in the 55th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida →

Medicare billing

Part B allowed, 2024

$865

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ClopidogrelClopidogrel Bisulfate	34	$668
Atorvastatin Calcium	14	$289
Pantoprazole Sodium	12	$155

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Wellington

Mark RothenbergWellington$200K
Arthur LeeGainesville$1.8M
Santhosh MathewsBradenton$1.4M
Siddharth WayangankarJacksonville$1.2M
Patrick CambierTrinity$901K
Zahid AminOrlando$635K
Rohit AminPensacola$560K
Eduardo de MarchenaMiami$498K
Dominick AngiolilloJacksonville$387K
Miguel DiazHialeah$383K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →